Trial Profile
A Randomized, Double-Blind, Placebo Controlled, Single-Dose Study to Assess the Initial Efficacy of Canakinumab (ACZ885) With Respect to the Adapted ACR Pediatric 30 Criteria in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms Beta-SPECIFIC-1
- Sponsors Novartis; Novartis Pharmaceuticals
- 16 Jan 2021 Results of secondary analysis characterizing distinct gene signatures for treatment response and non-response to canakinumab in sJIA patients published in the Arthritis and Rheumatology
- 16 Nov 2020 Results (n=286) of meta-analysis of 5 studies assessing relative efficacy and safety of canakinumab, anakinra, tocilizumab, and rilonacept in patients with active sJIA, published in the International Journal of Clinical Pharmacology and Therapeutics.
- 02 Mar 2018 Results pooled data from four SJIA studies (NCT00426218, NCT00886769, NCT00889863, NCT00891046), were published in the Clinical and Experimental Rheumatology.